Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Illumina and PHASE Partner to Advance Oncology Testing in the Greater Bay Area, Supporting the "Healthy China" Initiative

MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

NHS Wales and Illumina Expand Partnership to Advance Genomic Cancer Detection and Personalized Medicine

Unlocking Genomic Potential for Rare Cancers: Cancer52 and Genomics England’s Collaborative Approach

Tempus AI Launches Immune Profile Score to Enhance Precision in Immunotherapy for Advanced Cancer Patients

Home
/
update
/
details

Circular Genomics Unveils MindLight™: The First SSRI Antidepressant Response Test Based on Brain-Derived Biomarkers

NextEdge Admin

18 Sep 2024

2 min 8 sec

Circular Genomics, a global leader in circular RNA biomarkers for precision psychiatry and neurology, has launched MindLight, the first circular RNA biomarker-based test designed to predict whether a patient with major depressive disorder will respond to selective serotonin reuptake inhibitor (SSRI) antidepressants. This innovative test aims to streamline treatment for depression by providing personalized insights into SSRI response, offering a new standard in precision psychiatry.

"Currently, depression treatment often involves trial and error with medications, leading to delays in effective care. While SSRIs are the most commonly prescribed antidepressants, less than half of patients respond positively," said Paul Sargeant, PhD, CEO of Circular Genomics. "MindLight uses a biomarker-based approach to help doctors quickly determine if SSRIs will be effective, allowing for a personalized treatment plan within a week."

Clinical data shows that only 41% of patients respond to SSRIs, while the rest may benefit from alternative treatments. MindLight leverages brain-derived circular RNA biomarkers, detectable in the blood, to predict SSRI response with 77% accuracy. Patients identified as "High Likelihood of Response" are 3.4 times more likely to benefit from SSRIs compared to those categorized as "Low Likelihood of Response."

MindLight is a simple blood test ordered by physicians, with results returned in 3-5 days, offering clear and actionable insights to guide personalized treatment decisions.